Testosterone therapy for perimenopause: separating signal from hype

What did @healing.endo.meno actually say?

The creator responded to a viewer experiencing hair loss while using testosterone cream, attributing it to testosterone converting to DHT (dihydrotestosterone). She suggested lowering the dose, skipping doses, using spironolactone or finasteride if prescribed, or trying over-the-counter saw palmetto. She also shared that switching from cream to injections resolved her own breakouts, speculating that subcutaneous delivery may reduce DHT conversion.

The advice was structured around a reasonable decision tree: reduce dose first, add a DHT blocker second, change delivery method third. She was clear about telling viewers to talk to their provider before adjusting doses, which is the right call. She also mentioned checking DHT levels, which is genuinely useful guidance.

Does the science back this up?

Mostly, yes, though some of the nuance gets lost. The DHT conversion pathway is real and well-documented, and it is a legitimate cause of androgenic alopecia and acne in women using testosterone. The evidence on whether delivery method actually changes DHT conversion rates is thinner than she implies.

Testosterone does convert to DHT via the enzyme 5-alpha reductase, and this can trigger androgenic side effects in genetically susceptible women. A 2019 paper by Glaser and Dimitrakakis in Maturitas confirmed that androgenic side effects including hair loss are reported in a subset of women on testosterone therapy, with dose being the primary modifiable factor. Spironolactone is a legitimate androgen receptor blocker used off-label for this, and finasteride is a genuine 5-alpha reductase inhibitor. Both have real clinical use here. Saw palmetto (Serenoa repens) has limited but real evidence, including a small 2021 randomized trial by Wessagowit et al. in Journal of Dermatological Treatment, showing modest benefit in androgenic alopecia, but effect sizes are small.

What did they get wrong (or right)?

The delivery method claim deserves scrutiny. She says switching from cream to injections stopped her breakouts, reasoning that "maybe I'm not converting as much to DHT." That is a reasonable hypothesis but not well-supported by direct evidence. Transdermal testosterone can produce localized high concentrations at the application site, which may drive local DHT production in the skin, but systemic DHT conversion is not clearly lower with injections. Some data actually suggest injections produce higher peak DHT levels due to supraphysiologic testosterone spikes. A 2010 study by Borst et al. in Clinical Endocrinology noted that testosterone esters administered by injection produced significant DHT elevation.

She also mispronounced spironolactone as "spiralic tone" and saw palmetto as "Sopometto," which is a minor issue but could confuse viewers trying to look these up. She correctly framed spironolactone as a diuretic and noted it may help with bloating, which is accurate. She got the finasteride recommendation right and the dosing caution on saw palmetto is reasonable consumer advice.

What should you actually know?

If you are a woman on testosterone therapy experiencing hair loss, the mechanism she describes is real: DHT is the likely culprit, and dose reduction is the first sensible step. But the path from there is not a simple over-the-counter fix.

• Spironolactone requires a prescription and monitoring. It affects potassium levels and blood pressure, and should not be self-initiated.
• Finasteride carries a pregnancy warning and is teratogenic. It is sometimes used in postmenopausal women but requires a prescriber who knows your full history.
• Saw palmetto has limited evidence. It is not a substitute for medical management if hair loss is significant.
• Checking your serum DHT level is genuinely useful before adding blockers, as she suggests. Some women on low-dose testosterone will have normal DHT and the hair loss may have a different cause entirely.
• The injection versus cream DHT claim is not settled. Do not switch delivery methods solely based on this reasoning without talking to your prescriber about the actual tradeoffs for your situation.

The creator is sharing personal experience alongside real clinical concepts, which is a useful combination, but the personal experience parts should not be treated as generalizable evidence.